What is Generate Biomedicines, Inc. 's R&D?

Generate Biomedicines, Inc. (GENB) reported R&D of $57.81M in Q1 2026.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Generate Biomedicines, Inc. GENB R&D

R&D at other companies

RepligenRGEN

$14.46M+19.3%

Sensata TechnologiesST

$31.9M-13.3%

AppFolioAPPF

$49.63M+13.4%

SynapticsSYNA

$94.5M+6.7%

TFX

TeleflexTFX

$44.39M+75.5%

Silicon LaboratoriesSLAB

$88.59M+0.4%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's R&D?: Generate Biomedicines, Inc. (GENB) reported R&D of $57.81M in Q1 2026.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.